Harliku Tablet
Product Images NDC 70709-112

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Harliku (NDC 70709-112). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cycle Pharmaceuticals Ltd., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (Bottle Label)

This text provides important information about a medication dispersed by Cycle Pharmaceuticals Ltd in the UK and manufactured by Rivopharm SA in Switzerland. It includes details on how the medication should be stored, the recommended dosage, and a warning to keep it away from children. Additionally, the text mentions the NDC number, tablet strength, quantity, and expiry details.*

FDA Label Image

Principal Display Panel (Carton Label)

This is a medication information with details such as the manufacturer, dosage, inactive ingredients, storage instructions, NDC number, and contact information for Cycle Pharmaceuticals Ltd. The medication is nitisinone in tablet form containing 2mg of the active ingredient. It is recommended to keep out of reach of children and store at room temperature. For any questions or concerns, individuals can contact Cycle Pharmaceuticals Ltd at 1-855-831-5413.*

FDA Label Image

Image Description (Cyclelogo)

FDA Label Image

Figure 1 Structural Formula (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.